Physician profile
William Cohen
NPI 1992745087
$6,869.38
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $444 · 2020: $1,304 · 2021: $1,904 · 2022: $1,700 · 2023: $1,316 · 2024: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,516.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,053.38 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $625.93 | 2019-2024 | Breztri, Farxiga |
| Lilly USA, LLC | $548.43 | 2019-2024 | Mounjaro, Trulicity |
| Amarin Pharma, INC. | $523.96 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $471.89 | 2019-2023 | |
| Amgen INC. | $446.43 | 2020-2023 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $335.28 | 2020-2024 | Xifaxan |
| Abbvie INC. | $305.38 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $271.23 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $253.35 | 2019-2022 | |
| Harmony Biosciences LLC | $247.01 | 2022-2024 | Wakix |
| Bayer Healthcare Pharmaceuticals INC. | $241.73 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.98 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $194.81 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $152.64 | 2019-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.